SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
______________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 18, 2010
PAR PHARMACEUTICAL COMPANIES, INC.
(Exact name of registrant as specified in its charter)
| | |
Delaware | File Number 1-10827 | 22-3122182 |
(State or other jurisdiction of | (Commission File Number) | (I.R.S. Employer |
incorporation or organization) | | Identification No.) |
| |
300 Tice Boulevard, Woodcliff Lake, NJ | 07677 |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number , including area code: (201) 802-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07 Submission of Matte rs to a Vote of Security Holders
Par Pharmaceutical Companies, Inc. (the “Company”) held its annual stockholders’ meeting on May 18, 2010. At the annual meeting, the Company’s stockholders (i) elected Melvin Sharoky to serve as a Class II director of the Company for a three-year term expiring at the 2013 annual meeting of stockholders, (ii) ratified Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the 2010 fiscal year, and (iii) approved the non-binding advisory vote on the Company’s 2009 executive compensation programs and policies for the Named Executives (as described in the Compensation Discussion and Analysis set forth in the Company’s Proxy Statement filed with the Securities and Exchange Commission on March 31, 2010).
The following are the voting results for these p roposals:
PROPOSAL 1 – Election of Class II director for a three-year term expiring at the 2013 annual meeting of stockholders:
For
Withheld
Broker Non-Votes
Melvin Sharoky
26,707,291
1,198,041
3,009,576
PROPOSAL 2 – Ratification of D eloitte & Touche LLP as the Company’s independent registered public accounting firm for 2010
For
Against
Abstain
Broker Non-Votes
30,406,129
478,241
30,536
2
PROPOSAL 3 – Non-binding advisory vote on the Company’s 2009 executive comp ensation programs and policies for the Company’s Named Executives
For
Against
Abstain
Broker Non-Votes
28,843,659
1,296,392
774,852
5
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Dated as of: May 20, 2010
PAR PHARMACEUTICAL COMPANIES, INC.
(Registrant)
/s/ Thomas J. Haughey
Thomas J. Haughey, Executive Vice President, Chief
Administration Officer and General Counsel
3
